These top hits highlight both expected and underexplored targets consistently altered in AD plasma across cohorts, including those with established ties to lipid metabolism (APOB and GPD1), cholinergic signaling and/or treatment response (ACHE and VAT1) and synaptic integrity (NPTXR), as well as novel targets linked to cytoskeletal regulation (ARPC2) and RNA metabolism (PA2G4 and RPS12). This evidence concerns the gene ARPC2 and Alzheimer disease.